Friday, Amneal Pharmaceuticals Inc (NASDAQ:AMRX) reported fourth-quarter 2023 revenues of $616.98 million, up 1% Y/Y, missing the consensus of $634.23 million.
The increase was driven by AvKARE revenues growing 38% due to new launches and Specialty revenues growing 2% driven by key branded products, partially offset by Generics revenues declining 9% as the strong performance of biosimilars and complex generics was offset by the timing of orders.
Amneal Pharmaceuticals’ adjusted EPS decreased 39% to $0.14, beating the consensus of $0.09.
Net …